NVS — Novartis AG
Price when we picked it (Oct 5, 2026)
$141.02
Target: $156.29 (+10.8%)
P/E Ratio
21.3
P/E Forward
14.3
Dividend
3.36%
Market Cap
$268B
EPS
$6.62
Consensus
Hold
What they do
Novartis (Basel, Switzerland; CEO Vas Narasimhan since 2018; ~75,300 employees) is one of the world's largest pharmaceutical companies and a 'pure' branded-medicines business: it spun off Alcon (eye care) in 2019 and Sandoz (generics) in 2023, so all its revenue comes from patented medicines across four areas — oncology, immunology, neuroscience and cardio-renal-metabolic.
Its last reported quarter (April–June 2026, published July 21) reads like this, with sales and growth at constant currency: Cosentyx $1.824 billion (+10%), Kisqali for breast cancer $1.695 billion (+43%), Kesimpta for multiple sclerosis $1.424 billion (+32%), Entresto for heart failure $1.181 billion (−51%, it lost patent protection), Pluvicto for prostate cancer $651 million (+43%), Scemblix for leukemia $562 million (+89%) and Leqvio for cholesterol $480 million (+59%). Total sales: $14.408 billion (+3% in dollars). The old is falling and the new is growing twice as fast.
What's new since our first purchase (September 16, 2026): on September 18 the CHMP — the committee that advises the European Medicines Agency — recommended approving Cosentyx for polymyalgia rheumatica, an inflammatory disease common in people over 50 that is treated mostly with steroids; it would be the first medicine of its kind (an IL-17A inhibitor) approved for it in Europe. And on October 2 Novartis bought from China's Abogen Biosciences the worldwide rights to ABO2203, an experimental messenger RNA medicine that gives the body the instructions to make its own antibody and wipe out the B cells that drive autoimmune diseases such as lupus and rheumatoid arthritis.
Why we like it
Three reasons to add more.
- NOTHING IN THE BUSINESS THAT PAYS BROKE: since our first purchase no new blow has hit the medicines that bring in revenue; the negative news was the detail of the ALS failure (a 251-patient study of a medicine that sells nothing) and the stock barely reacted. What it sells keeps growing — Kisqali +43%, Kesimpta +32%, Scemblix +89%, Pluvicto +43% in the second quarter — and Cosentyx, its #1 product, is going after a new disease in Europe.
- THE EARNINGS DIP LASTS ONE YEAR: Novartis expects 2026 core operating income to fall low single digits because of Entresto's patent loss; analysts expect $8.87 per share in 2026 (−1%) and $9.84 in 2027 (+11%). At $141.02 you pay 14.3 times that 2027 profit, 17% below its 52-week high ($170.46) — and the stock is still where we bought it in September while the S&P 500 rose 2.9%.
- IT PAYS YOU TO WAIT AND IT CHANGED HOW IT BETS: a ~3.4% dividend with 29 consecutive increases, a share buyback with $5.6 billion still to execute as of June 30 and an Aa3/AA− credit rating. And its first bet after the blow, Abogen, risks only $575 million upfront (7% of the deal's maximum value): the other $7.2 billion is paid only if the medicine hits its milestones. A fund that owns the shares, Point Capital, summed it up as a deal with a 'better risk profile'.
The honest part of the case: consensus is still Hold with a $156.29 target (+10.8%). We're buying again for price, for income and for earnings that grow again in 2027, not for a quick rebound.
Key Risk
#1: the labs and the acquisitions have to win back trust. Between August 24 and September 16, 2026 Novartis stumbled four times: it paused 8 studies of its cell therapy rap-cel in autoimmune diseases after 3 patient deaths; pelacarsen (heart) failed in a study of ~8,300 patients; del-desiran — the crown jewel of the $12 billion Avidity acquisition — failed in myotonic dystrophy type 1; and its ALS medicine failed in 251 patients. Its new bet, Abogen's ABO2203, is only in Phase I and its first published data in autoimmune diseases come from 3 patients. Others:
- patents: Entresto fell −51% in the second quarter, which is why 2026 core operating income falls; and the US patents on Cosentyx, Kisqali and Kesimpta — its three best-selling medicines, almost 38% of first-half sales — expire between 2029 and 2031;
- the franc: the dividend is declared in Swiss francs and the franc has weakened against the dollar — in March 1 franc was worth ~$1.28 and on October 5 $1.20, so the same CHF 3.70 would be ~$4.45 per share instead of $4.74; it is also paid once a year and Switzerland withholds 35% (partly reclaimable under your country's tax treaty);
- balance sheet: net debt of $39.4 billion as of June 30, almost double December's;
- governance: Artisan Partners demanded board changes and a committee dedicated to reviewing acquisitions;
- Hold consensus with a $156.29 target — Wall Street expects no quick rebound.
This is educational and informational content, not financial advice. Always consult a qualified financial advisor before making investment decisions.
Vectorial Data picked NVS on Sep 16, 2026 at $140.58.
Full Research
What it does. Novartis AG (NYSE: NVS; SIX: NOVN; Lichtstrasse 35, Basel, Switzerland; CEO Vas Narasimhan since 2018; ~75,300 employees; created in December 1996) is a global pharma focused exclusively on branded medicines: it spun off Alcon (eye care) in 2019 and Sandoz (generics) in 2023. Four therapeutic areas: oncology, immunology, neuroscience and cardio-renal-metabolic. Top brands in Q2 2026 (sales and growth at constant currency): Cosentyx $1.824 billion (+10%), Kisqali $1.695 billion (+43%), Kesimpta $1.424 billion (+32%), Entresto $1.181 billion (−51%), Pluvicto $651 million (+43%), Tafinlar+Mekinist $581 million (0%), Jakavi $576 million (+8%), Scemblix $562 million (+89%), Ilaris $550 million (+15%), Leqvio $480 million (+59%), Zolgensma $365 million (+20%), Fabhalta $225 million (+88%), Lutathera $225 million (+8%) and Rhapsido $64 million (launch).
Results (Q2 2026, published July 21). Net sales $14.408 billion (+3% in dollars, +1% at constant currency); core operating income $5.940 billion (flat), core margin 41.2% (−70 basis points); core EPS $2.41 (0% in dollars, −1% cc); net income $3.257 billion (−19%); free cash flow $5.561 billion (−12%). H1 2026: sales $27.521 billion (+1% in dollars, −2% cc), core operating income $10.837 billion (−6% / −7% cc), core EPS $4.39 (−6% / −8% cc), core margin 39.4%. 2026 guidance reaffirmed: net sales grow low single digits and core operating income falls low single digits (constant currency). Mid-term goal: sales growing at a 5–6% compound annual rate between 2025 and 2030. 2025 base: net sales $54.532 billion (+8%), core operating income $21.889 billion (+12%), core EPS $8.98 (+15%). Vas Narasimhan on July 21: 'Novartis delivered a solid second quarter, returning to sales growth driven by Kisqali, Kesimpta, Scemblix and Pluvicto... we remain on track to deliver our full-year guidance and mid-term outlook.'
The September 2026 blow. (1) September 4: pelacarsen (developed with Ionis) missed its primary endpoint in the Phase III Lp(a)HORIZON study, in ~8,300 patients with elevated lipoprotein(a) and established cardiovascular disease; the failure also dragged down Amgen and Eli Lilly, which chase the same target. (2) September 8: del-desiran (delpacibart etedesiran) missed its primary endpoint in the Phase III HARBOR study in myotonic dystrophy type 1 — it showed activity on secondary endpoints and Novartis said it is evaluating the full dataset with regulators. It was the centerpiece of the $12 billion Avidity Biosciences acquisition, announced in October 2025 and closed on February 27, 2026. Bloomberg reported the biggest one-day drop on record for the stock; ~$30 billion of market value evaporated over the week. (3) September 16: Novartis cancelled its TREM2-targeted ALS program after a Phase II failure. (4) September 10: Artisan Partners (David Samra) publicly called for changes to the board over the R&D and M&A failures; Reuters headlined that for Novartis 'M&A is both the disease and the cure'. On the other side of the ledger: on September 1 remibrutinib (Rhapsido) won two Phase III studies in relapsing multiple sclerosis against teriflunomide, with no liver-safety signal; on September 15 the FDA approved the first radioligand equivalent of Lutathera (from Curium); and on the 16th Novartis paid $125 million to Sironax for a blood-brain-barrier platform.
2026 pipeline. Q2 approvals: Rhapsido (remibrutinib) approved in the European Union and by Japan's MHLW for chronic spontaneous urticaria — the first BTK inhibitor approved in that disease; Itvisma approved in the EU as the only gene replacement therapy for a broad spinal muscular atrophy population; Fabhalta granted traditional FDA approval as the first complement inhibitor to slow kidney function decline in IgA nephropathy. Kisqali received FDA pediatric exclusivity (6 extra months on all its Orange Book patents) and its 6-year follow-up in early breast cancer showed an overall survival benefit. A Biologics License Application for accelerated approval of del-zota in Duchenne muscular dystrophy was submitted to the FDA. The WHO prequalified Coartem Baby, the first antimalarial developed for newborns weighing 2–5 kg.
Dividend and capital. A single payment a year, in March. For 2025 the board proposed CHF 3.70 per share (+5.7% over CHF 3.50), the 29th consecutive increase since Novartis was created in December 1996; approved at the March 6, 2026 annual meeting. The ADR received $3.08116 on March 16, 2026: the gap versus the 3.42% gross yield is the 35% Swiss withholding tax (reclaimable down to 15% under treaty). Buyback: an up-to-$10 billion program announced in July 2025, with $5.6 billion still to execute; in H1 2026 it repurchased 18.2 million shares for $2.8 billion on the Swiss exchange's second trading line. Net debt: $39.4 billion at June 30, 2026 versus $21.9 billion at the end of 2025 — the jump comes from $15.3 billion of M&A and intangible-asset outflows and the $9.1 billion annual dividend. Credit ratings Aa3 (Moody's) and AA− (S&P Global).
Stock. $140.58 at the open (September 16, 2026); market cap ~$263.6 billion; 52-week range $121.57–$170.46 (~18% below the high); P/E 20.9x TTM / 14.1x forward; reported EPS $6.63 (the 'core' figure runs near $9). The stock is roughly flat on the year despite September's collapse. Hold consensus (12 analysts per S&P Global), average target $156.56 (+11.4%), range $130–$185.
Risks. (1) Pipeline: three public stumbles in under two weeks (pelacarsen, del-desiran, ALS); the deeper question is whether R&D and acquisitions justify the price paid. (2) Patents: Entresto −51% cc in the quarter, Promacta/Revolade −65%, Tasigna −58%, Xolair −25%; 2026 core operating income is guided to fall. (3) Governance: Artisan Partners demanding board changes; public pressure on the CEO. (4) US pricing: the pricing agreement with the US government is already reflected in 2026 guidance and the 2025–2030 goal. (5) Balance sheet: net debt nearly doubled in six months. (6) New competition: first radioligand generic of Lutathera approved on September 15, 2026. (7) Dividend currency and tax: declared in Swiss francs, paid once a year, and Switzerland withholds 35%. (8) Hold consensus with a $156.56 target: Wall Street expects no quick re-rating.
Update October 5, 2026 — Rebuy (Position #200)
Entry price $141.02 (October 5, 2026 open on the NYSE; 1 ADR = 1 share on the Swiss exchange SIX). Previous purchase: #184 on September 16, 2026 at $140.58 (+0.3% since then). P/E 21.3x on reported earnings per share over the last 12 months ($6.62); 14.3x on the core earnings per share analysts expect for 2027 ($9.84, 10 analysts) and 15.9x on 2026 ($8.87, 9 analysts). Dividend ~3.36% (on the $4.74 gross per ADR paid in March 2026). Market value ~$268 billion. 52-week range $121.57–$170.46 (17% below the high); in 2026 the stock is up 2.3% (2025 close: $137.87).
What the stock did between the two purchases. It reached $146.88 at the September 28 close (+4.5% over the #184 entry) and gave it back in two sessions: −2.2% on September 30 and −1.1% on October 1, days when the US health-care sector fund (XLV) fell 1.4% and 1.3%. From the September 16 close to the October 5 close: NVS +1.6% ($138.70 → $140.93), XLV −0.2% and S&P 500 +2.9%. In Switzerland the share went from CHF 114.28 to CHF 116.48 (+1.9%) while the franc slipped from $1.2117 to $1.2036. Its beta is 0.47: historically it moves less than half as much as the market.
What's new since September 16. (1) ALS, the detail: the cancelled program was VHB937 (lifonebart), an antibody designed to stabilize the TREM2 protein; the Phase II ASTRALS study, with 251 patients with early ALS, missed its primary and secondary goals. Novartis keeps testing it in Alzheimer's and will present full data at the 37th International Symposium on ALS/MND in December 2026. The US shares traded 'marginally higher' on the news. (2) Cosentyx in polymyalgia rheumatica (September 18): the European Medicines Agency's CHMP recommended approving it for adults with an inadequate response to steroids or who relapse while tapering them. In the Phase III REPLENISH study (27 countries; 300 mg and 150 mg doses) it doubled the sustained remission rate at week 52 versus placebo and met all secondary goals, with a safety profile in line with what was known. It would be the first IL-17A inhibitor approved in Europe for that disease; the European Commission's decision usually comes ~2 months after the CHMP opinion. Cosentyx is its #1 product ($1.824 billion in the second quarter, +10%). (3) Abogen (October 2): Novartis obtained exclusive worldwide rights to ABO2203, an mRNA-encoded 'T-cell engager' (CD19xCD3): instead of making the antibody in a plant and injecting it, it gives the body the instructions to produce it, wrapped in lipid nanoparticles, to wipe out the B cells that drive autoimmune diseases. It pays $575 million upfront plus up to $7.2 billion in development, regulatory and sales milestones (total up to $7.8 billion), royalties on future sales and options on other Abogen RNA programs. ABO2203 is in Phase I in China (started December 2024; 66 planned participants). The first human data, published in the journal Cell in September 2026, show in 3 patients with refractory secondary immune thrombocytopenia a rapid and complete depletion of B cells in the blood, sustained depletion in the bone marrow and platelet recovery over six months; in lymphoma (9 patients, presented at AACR 2026) there were no dose-limiting toxicities. Fiona Marshall, president of biomedical research at Novartis: it is 'an innovative approach that could complement existing therapeutic modalities'. The stock fell 0.5% that day. Gillian Hollenstein of Point Capital Navigator Fund (a shareholder): 'this deal has a better risk profile, as they pay a smaller amount upfront', although Novartis 'needs later-stage deals with a higher level of predictability'. It is the flip side of Avidity: $575 million upfront (7% of the maximum value) versus $12 billion in cash. (4) Analysts: consensus barely moved — 11 analysts with an average target of $156.29 (previously $156.56), median $160.15 and range $130–$185; average recommendation Hold (3 strong buy, 2 buy, 6 hold, 1 sell). Bank of America (Sachin Jain) reiterated Buy on October 5. For the third quarter consensus expects core earnings of $2.24 per share (vs $2.25 a year earlier); for 2026, $8.87 (−1.2% vs $8.98 in 2025) and for 2027, $9.84 (+10.9%).
Two facts from before September 16 that were missing from the profile. (a) rap-cel: on August 24, 2026 Novartis paused 8 studies of rapcabtagene autoleucel — its CD19-directed CAR-T cell therapy — in autoimmune diseases (lupus, systemic sclerosis, vasculitis, rheumatoid arthritis, myasthenia gravis and multiple sclerosis, among others) after 3 deaths from a severe inflammatory syndrome known as IEC-HS; the cancer studies continue, and the company is reviewing the cases with independent safety boards. This is the context for Abogen: ABO2203 goes after the same target — B cells carrying CD19 — by another route. (b) del-zota: on September 8 the FDA accepted for review the accelerated-approval application for del-zota (from Avidity) in Duchenne muscular dystrophy amenable to exon 44 skipping, with priority review; the confirmatory Phase III SAFARI44 study has already started. Guggenheim estimates $430 million in 2033 sales with a 95% probability of success. On the failures, investor relations said it 'does not foresee future development' of pelacarsen and plans to 'continue exploring del-desiran' with possible further studies.
Why we're buying again. (1) Same price, less uncertainty: the four lab stumbles came out between August 24 and September 16; in the following three weeks no new one hit the medicines that bring in revenue, and the most important regulatory news was favorable for its #1 product. (2) Earnings dip in 2026 because of Entresto, but consensus expects +10.9% in 2027: at $141.02 that is 14.3 times. (3) Discipline in its bets: Abogen risks 7% upfront and the rest depends on results — the opposite of Avidity. (4) Income: 29 consecutive dividend increases (CHF 3.70 per share for 2025); the 2026 proposal will come with the annual results on February 3, 2027 and would be paid in March — it would be the 30th increase if the board raises it, which is not guaranteed.
The honest part. The franc weighs on the dividend: the CHF 3.70 for 2025 was $4.74 per ADR (1 franc ≈ $1.28 in March); at the October 5 exchange rate (1 franc = $1.2036) it would be ~$4.45, ~3.2% on the purchase price, before the 35% Swiss withholding. Consensus is still Hold; since the first purchase the stock has lagged the S&P 500 (+2.9%); ABO2203 is in Phase I with 3 published autoimmune patients; the US patents on Cosentyx, Kisqali and Kesimpta (almost 38% of first-half sales) expire between 2029 and 2031 (BioSpace); net debt is $39.4 billion.
Upcoming dates. Third-quarter results: October 27, 2026. 'Meet Novartis Management 2026' in London: November 19, 2026. European Commission decision on Cosentyx in polymyalgia rheumatica: ~2 months after September 18. Full lifonebart ALS data: December 2026. Ianalumab (Sjögren's disease) is already under review in the US, the European Union and Japan. 2026 annual results: February 3, 2027.
More picks in Healthcare
- BDX — Becton Dickinson
- ZTS — Zoetis Inc
- GILD — Gilead Sciences
- HCA — HCA Healthcare, Inc.
- RHHBY — Roche Holding AG
- DHR — Danaher Corporation
More picks from Switzerland
See all picks from Switzerland →This is not financial advice. Consult a certified financial advisor.
The author may hold positions in the securities discussed.
Past performance does not guarantee future results.